Compare CHOW & TOVX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CHOW | TOVX |
|---|---|---|
| Founded | 2014 | 2001 |
| Country | Hong Kong | United States |
| Employees | N/A | 16 |
| Industry | Computer Software: Prepackaged Software | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.8M | 14.7M |
| IPO Year | N/A | 2012 |
| Metric | CHOW | TOVX |
|---|---|---|
| Price | $0.44 | $0.28 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $1.00 |
| AVG Volume (30 Days) | 323.6K | ★ 22.2M |
| Earning Date | 06-17-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 89.07 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $10.80 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.33 | $0.16 |
| 52 Week High | $12.05 | $0.86 |
| Indicator | CHOW | TOVX |
|---|---|---|
| Relative Strength Index (RSI) | 48.94 | 42.56 |
| Support Level | $0.43 | $0.27 |
| Resistance Level | $0.45 | $0.31 |
| Average True Range (ATR) | 0.03 | 0.02 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 23.89 | 2.37 |
ChowChow Cloud International Holdings Ltd is providing one-stop cloud solutions that support companies across the IT industry value chain throughout their entire cloud transformation journey from consulting, deployment and migration to cloud environment building and management. Its business comprises (i) digital transformation consulting services consisting of cloud suitability assessment (ii) professional IT services comprising of capabilities designed to facilitate seamless cloud integration and digital transformation, (iii) AI-powered proactive cloud managed services covering all aspects of day-to-day cloud maintenance and support, and (iv) IT infrastructure solutions covering on-premise private cloud setups and public cloud integrations including infrastructure applications.
Theriva Biologics Inc is a clinical-stage pharmaceutical company developing a novel oncolytic adenovirus (OV) platform to address devastating cancers with high unmet needs. It is a clinical-stage program VCN-01, designed to break down the tumor stroma, and its preclinical-stage program VCN-11 leverages its proprietary Albumin Shield Technology to protect systemically administered oncolytic viruses from the host immune system. Product Candidates includes SYN-004 (ribaxamase) and SYN-020.